Everything important about the vision, our mission, the business and the people who shape CompuGroup Medical.
Vision & Mission
Information, downloads and contacts for representatives of press and other media.
We promote dialog in the healthcare sector and ensure that costs are saved in a meaningful way. Everyone should benefit from medical progress with the help of IT.
CompuGroup Medical (CGM) is looking back once again at a solid quarter. Although the second quarter of 2020 was significantly affected by the economic impact of the COVID-19 pandemic, Koblenz based CompuGroup Medical, one of the largest providers of e-Health solutions worldwide, is well on track financially. CGM is expecting continued positive business performance due to increasing digitizing in healthcare and corresponding measures by the government and the economy. Against this background, CGM is well set to continue the current investment and growth path, supported by a share placement at the end of June resulting in gross proceeds of approximately EUR 341 million.
Frank Gotthardt, founder and CEO of CompuGroup Medical, "Our company showed its strong resilience and solid business model in the face of uncertainties of a pandemic in the first and especially in the second quarter. We have seen many people becoming directly aware of the benefits of digitization in healthcare during this time. In the third quarter, healthcare professionals and patients will be able to benefit even more from the opportunities of digital communication. Since the CGM e-health connector KoCoBox MED+ has been approved and is now being rolled out, emergency data and electronic medication plans on a health card will become normal along with digital communication between service providers. All of this encourages us to continue with our consistent growth course from past years."
Overall, CGM was fully on track in the second quarter and generated group revenues of EUR 179.9 million. Adjusted EBITDA grew by 1% to EUR 44.6 million year-on-year. The prior year quarter had been characterized by high installation revenues for the Telematics Infrastructure (TI) in German doctors’ practices with revenues of EUR 186.6 million. Without these TI one-time revenues, group revenues grew organically by 6% in spite of the effects and uncertainties from COVID-19, and recurring revenues significantly increased by 10%. Due to the July 2020 approval of KoCoBox MED+ as an e-health connector, CGM expects good one-time revenues in the second half of the year from the software upgrade in more than 55,000 practices. In addition, the rollout of the Telematics Infrastructure can now begin in pharmacies.
Adjusted Group EBITDA increased from EUR 44.3 million (pro-forma) to EUR 44.6 million in the second quarter of 2020. The operating margin is still at a high level with 25% (previous year: adjusted 24%). CGM generated a consolidated profit of EUR 16.3 million in the second quarter (previous year: EUR 14.2 million). Adjusted earnings per share (diluted) were EUR 0.38, exactly at the previous year's level of EUR 0.38 in spite of the increased number of shares outstanding following the share placement.
Capital expenditures stood at EUR 13.5 million, slightly below the previous year (EUR 14.3 million). Operating cash flow in the reporting period was characterized by a decrease in payables and an increase in inventory and income tax receivables. Adjusted free cash flow was at EUR -0.8 million (previous year EUR 23.5 million), which is primarily due to high, one-off payments from TI connections in the previous year. Net debt as of June 30, 2020 was at EUR 123.2 million and thus EUR 343.7 million lower versus year-end 2019 (EUR 466.9 million). As of June 30, 2020, the company employed 5,826 people, 369 more than at the end of the previous year quarter. Including the successfully concluded takeover of the Cerner portfolio, which took place after the reporting date of June 30, 2020, the company employs more than 6,100 people.
CGM is increasing its guidance for the full year. Including the acquisition of parts of the Cerner portfolio in Germany and Spain, which was finalized on July 1, revenues are now expected in the range of EUR 820 million to EUR 860 million. Guidance for adjusted EBITDA is also raised to a new range of EUR 205 million to EUR 220 million.
Revenues in the Ambulatory Information Systems segment were down 9% year-on-year because of the especially high sales from the TI rollout in the previous year quarter as a one-off effect. Recurring revenues significantly increased year-on-year by 8% to EUR 81.4 million, representing 77% of total segment revenues. Organic revenue growth excluding TI stood at 7% in the second quarter of 2020.
Business in the Pharmacy Information Systems (PCS) segment was positively affected in the second quarter by successful sales of additional modules for cashpoints in German pharmacies. Revenues increased by 6% to EUR 29.6 million (previous year: EUR 27.8 million). Recurring revenues increased by almost 9% year-on-year and reached EUR 18.9 million. The share of recurring revenues increased by one percentage point to 64% of the segment's revenues. Revenues also increased organically by approximately 6%. Adjusted EBITDA was EUR 8.0 million (previous year: EUR 6.0 million) with an operating margin of 27% (previous year: 21%).
The Hospital Information Systems (HIS) segment increased revenues in the second quarter by 4% to EUR 33.4 million (previous year: EUR 32.3 million). Recurring revenues increased by 12% to EUR 21.8 million. Thus, the portion of recurring revenue in the segment's revenues increased from 60% to 65%. Adjusted EBITDA was EUR 5.5 million after EUR 1.6 million in the previous year quarter, which is an increase of the operating margin to 16% (previous year: 5%).
The Consumer & Health Management Information Systems (CHS) segment increased revenues by 6% to EUR 10.6 million (previous year: EUR 9.9 million), which mainly resulted from the CGM LIFE division that significantly increased its business with private health insurance companies. Organic growth was also 6%. Adjusted EBITDA of EUR 1.4 million was slightly under the previous year quarter (EUR 1.5 million) due to increased development costs.